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WBST&\CT: 
Objective:  To determine if  emergency phq iiciatls~  IEP) 
UFG o!'drcq7eridr>! i-12s chiingrri sirice 1112 United Scales Food 
a.nd Driig Aclniinihzratio~:  (FDA) warning of December 2001 
coxicerning QT irikrrt al proiorgatioi:,  iorsarie Je poi~tes, 
2nd  s~~cidcii  de:.r",l:  and  ro  qu:.r>  EP nl,ii?iofij rcgzrding 
droy?eri:'.cl  hefclre 2nd ~ifter  tli~  FDA. i;var.r,ing aiid regarding 
potcx"lal aItcrilbt:il;c  drugi. 
Methods:  An internet-based survey was designed with 
y~~eslions  regarding droperidol use in the emergency de- 
partment (ED).  Data coiiected included EP demographics, 
use of droperidcd before and ~ifier  the FDA warniiig, use of 
alterilative drugs, and incidence of arrhythmias.  A repre- 
sentative sample of EPs were contacted by e-!nail and asked 
to complete the survey. 
Results: A total of 2,000 e-mails resulted in 506 (25%)  com- 
plered surveys.  There was no aecond mailing. Respond- 
ers"  average years practicing was 12.6 2  9.2. EP responders 
worked in pivatelcommunity  (n=278, 55%). academic/ 
county jn=187,37%), and HMO (i1=41,89)  hospitals. The 
~~~ajority  (11~455,  90%) used droperidol and were aware of 
the FDA warning (n=460.9 i %). Droperidol was no longer 
avaiiable at i  22 (24%) ofthe respondents' EDs as aresult of 
the FDA warning. Prior to the FDA warning EPs who had 
used droperidcli used it as an antiemetic jn=408,90%), for 
conrroi of agiiaticm (n=330.73%);  for treatment of headache 
(n=247, 54%), and for treatment of vertigo jn=106. 23%). 
After the FDA warning, 387 (85%)  of EPs reported their use 
of droperidol had decreased or ceased altogether, and 68 
(158) always oh~btined  an elecrrocardiogra~n  prior to ad- 
ministraiion.  Of' tilose who used droperidol fix agitation: 
137 (42%) felt there were no other drugs with greater effi- 
cacy.  Haloperidol was the most cited alternative agent 
in=160, 79%) fc>c;i!o\+  ed by benzodiazepines (it=223,68%). 
Of those wl~o  usecl cira>peridoi  for antiernesis; 116 (28%)  felr 
there were no other drugs with  grealer efficacy than 
droperidoi: promethazine  was rhz  most cited  alternative 
agent (n=2OO. 64%). 'Two (0.4%  j EPs reported 21-rhythxnias 
in patients who received droperidol. Only 37 (8%) EPs re- 
ported  they  were unconcerned  with  potential  loss of 
droperidol frol-i~  the nlaritet, 
Conc%iasion: Basecl  031  this survey EP use of droperidol 
has decreased cirarnaticaliy as a result ofthe  FDA warning. 
However. EPs he!ieve  that there are fevv:  or no alternative 
anriernelic drugs that have an improved adverse ePfecl pro- 
file, 
Key words: droperidol. Ii~zpsine.  emergency medicine: FDA 
avarnilag 
INTRODUCTION: 
In December 2001 the FDA :ssued  a %Jack  box 
uars~ing~'  (E~glitc  11, ils  most sersous alert, c3n  the use 
of dropendoi, ;u~d  this bx,  a\ tollowed soon thereafter 
by 21 s~rmilar  \wa.r,arng  by the Canadfan Hedth Protec- 
t1si-i Erarich ' '  This walnang w a\ sn respocce kc3 con- 
rems s\  el pot? -ti;s,l prolonga~ios,~  of t5e QT Imiterb al. 
twwde de poineb, ;lid  s~iddeu  death after adminis- 
tratlm 239  dr~pendoi.'~  Prior to theie warnings, 
dnspei:nol was zxtensrvclj uscd 11:  the ED fot myralad 
mdlc;it~ons,  ~~sludmg  co-2 ti  ol of agdt~itiola  and p\yrlao- Cases of QT prolongation and/or torsades de pointes have been reported in patients receiving INAPSINE at doses 
at  or below recommended doses. Some cases have occurred in patients with no known risk factors for QT 
prolongation and some cases have been fatal. 
Due to its potential for serious proarrhythmic effects and death, INAPSINE should be reserved for use in the 
treatment of patients who fail to show an  acceptable response to other adequate treatments, either because of 
insufficient effectiveness  or the inability to achieve an  effective dose due to intolerable adverse effects from those 
drugs (see Warnings, Adverse Reactions, Contraindications, and Precautions). 
Cases of QT prolongation and serious arrhythmias (e.g.,  torsades de pointes) have been reported in patients 
treated with INAPSINE. Based on these reports, all patients should undergo a 12-lead  ECG prior to 
administration of INAPSINE to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males 
or 450 msec for females) is present. If there is a prolonged QT interval, INAPSINE should NOT be administered. 
For patients in whom the potential benefit of INAPSINE treatment is felt to outweigh the risks of potentially 
serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2-3 hours after 
completing  treatment to monitor for arrhythmias. 
INAPSINE is contraindicated in patients with known or suspected QT prolongation, including patients with 
congenital long QT syndrome. 
INAPSINE should be administered with extreme caution to patients who may be at  risk for development of 
prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, 
hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT  interval). Other risk 
factors may include age over 65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile 
anesthetics, and PV  opiates. Droperidol should be initiated at  a low dose and adjusted upward, with caution, as 
needed to achieve the desired effect. 
Figure I. FDA Black Box Warning for Use of Droperidol (InapsineB). 
sis,"12 nausea and emesis,13  l8 headache,lS " ver- 
tigo,?*-"  and atypical pain syndr~mes.~"~~  Dmperidol 
was commonly used by anesthesiologists for treat- 
ment of postoperahive nausea and vorniting (POW), 
constihtting 30% of the POW  market, with over 25 
million units sold in 2000.2Vn  its oral form, dsoperidol 
was used as an antipsychotic agent by psychiatrists, 
especially in Europe.' Before the FDA wa~ng,  only 
doses greater than 25 mg were col~cidered  to be at 
risk for QT interval proBongation and arrhythmia. 
Across the world, EPs. anesthesiologists, psychia- 
hists, and pl~amacists  reacted with skepticism to there 
new rertrictions on the use of droperidol.' 2s-35 The 
purpose of this survey study war to determine if 
droperidol use by EPs has changed since the FDA 
warning. 
METHODS 
Study Design and Population 
This survey study was specifically designed for, and 
addressed to practicing EPs in the United States, in- 
academic/universiQ>  countyipt~b- 
lic, p~ivate/communi@>  md  health maintenance orga- 
nizatioi~  (mO)  EDs. A questionnaire was de\ieloped 
in hyper text makup language (HTNIE) format tasii~g 
Dreamweaver (Macromedia,  Sari Francisco. Califor- 
nia), and a survey world wide web (WWW) page 
was set up on a dedicated server. Upon completion 
of  the HTML survey, data was collected using 
ColdFusion (Macromedia, San Francisco. Califor- 
nia) in an Access (Microsoft, Wedmsnd, Washing- 
ton) database for hi-ther andy  sis. This study was ap- 
proved by the hsdtk~tional  Review Board of the Uni- 
versity of California, Davis Medical Centeir. 
Survey Content and Administration 
The first section of the survey contained questions 
regauding El? demogr;~p%nics,  includil~g  type of hospi- 
tal staffed, surrounding population sewed, and years 
practicing emergency medicine. We obtained re- 
sponses on howledge  of the FDA waning and prior 
use of dropendo1  in the ED. Culrent availability of droperidol in the respondent's particular ED and dis- 
continuation after the FDA walling were also que- 
ried. The next section of the s~~~vey  involved ody  those 
physicians who use or had used droperado1 in the ED. 
Specific indicaeioras such as nausea and emesis, agi- 
tation. and headache were listed, and frequency of 
use of ciroperidol before and after the FDA war~~ing 
was detemined. Emergency physicians who contin- 
ued to use drope6dol despite the FDA !yarning were 
aslced if they now obtained an eelctrocxdioga-m  prior 
to administration. 3pinion regarding efficacy of 
droperidol and preferred alternative pharmaceutical 
agents for tl~e  Bndics?'bions  of agitkltlon and psychosis, 
as well as nausea and emesis, were queried. In addi- 
tion, adverse outcomes in the fom~  of arrhythmia or 
sudden death from droperidol administration were 
tabulated. Finally, EP opinion of the validity of the 
g and concern regarding loss of drope:r;ldol 
avi6lability altogether were also i~acluded  in the ques- 
tio~~raire. 
A;? e-r-mil conea~ning  La solacttation letter deialilng the 
pu~yos:  of tbc stvdy  a hy  perllnh lzrading to the 
xeeah web page v as wit  :o  a SB\I of2,000  EPc). E%cG- 
uonlc in21i  zddre4ces were obta~ned  raxadoady rn pro- 
pol-tlon ko  xnembsrahlp nulxber Lcrn published direc- 
ti;nes of  clx -4mesncdn Colkeg of Emergencq Pnj  sl- 
crars. Socsety of Academic Enxrgency Medicme. and 
Amersia~~  Aii?dt:my  oEEmergency Mcd~csne.  A sangle 
broadcast nnailing was perfornied In the Spnng of 
2002, and there were no repeat e-mails To emure 
pnvacy and freedom ofopls~~o~~,  no adenlifaer$  were 
s~.ied  foi respondent<.  such aa Hogging ori~~ternet  pro- 
vider (IP) s;- e-mail acldresses, ccjok~es,  ol survey 
coding 
Data Analysis 
Gompaa-isons  between drope~dol  use before and af- 
ter the FDA warning werc made asmg fne two-sample 
Vi~lcoxon  EU&  sum test for non-pa arnetric v;viables. 
Statibtical signlficai7ce is ascumed at a level of P < 
0~05~  Data are rcpdried a<?  mesn 2 standal d devia- 
tion. 
RESULTS 
Table 1.  Clinlczl lndrcatiolls for Droperidol use 111 !he  ED. 
n  -  6%) 
EPs who uie or used Droperidol  455  (100) 
Emesis 
Nausea 
Agitation 
Psychosis 
Headache 
Anxiety 
Vertigo 
Abdominal pain 
Chronic musculoskeletal pain 
Co~~scious  sedation 
Amnesia 
Chest pain 
From 2,080 e-mails iient out there were 506 (25%) 
fully completes$  surveys. There were 122 (6%) in- 
17alid e-man1 addresses, and one EP returned the e- 
mail u~~willmg  to pafl~cipate  in the seirvey, Respocd- 
ers' ak7erage  years practicing was 12.6 + 9.2, Elmer- 
gency phy\ician responders worked ira plrt atei~orn- 
mut~~fy  (n=27S,  55%). 3cadem1clci3untj {n=  187, 
37%),  anci HMO bn=4 1, 8%) i-~osp~taals.  One 11~1i.8- 
dred twes7ty four (25%  j dejcrlbed :heir pract~ce  set- 
iing as inner city, 299 (59%) a\ urban. and 83 ( 16%) 
as r~iral. The mkajo~itg'  (11~455.  90%) had  u\ed 
droperidol and were av,are of  the FDA warning 
(n=460,91%). Droperidol war i?o longer available 
in 122 (24%) ofthe  respondents ED3 following the 
FDA warning.  Pnor to the FDA warnzing 90% 
(n--408)  of EPs who had used droperidol, used it as 
an antiemet~c.  and 73% (11x330)  for ccsntsol of agita- 
tion. Eble  H l~sts  all ~Iinicd  indications  for si-soper'rdol 
ac indicated by the respondents. 
As a direct result of the FDA wafing, 85% (n=387) 
oEEPs reported theh use of dropekdol had decreased 
or ceased akogether (Figure 21, and this decline in 
frequency of use was significant (P  < 0.1400%).  The 
remaining 15% of EPs who still use droperidoi al- 
was s obtained an electrsc~~diogram  psior to admin- 
istration. Of those EPs who used droperldo" fw  rthc 
treatment of agitation in fhe ED, 42% (I  37) felt &ere 
were no other drugs with greater effncaey. Haloperk 
dol was the lnosl frequently c~ted  alternative agent 303 
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Figare 2, Frequency of Droperidsl Use before and after the FDA Warning 
79% (r-r=260)  foliorn7ed by benzodiazepines m 68% 
(n=223) (Table 2). Or" tho% who used ctroperidol 
for antierz~esis,  28% ((n=  1  I&)  felt there were no other 
&XI~S  with greater efilcacy, md  promethalzine was the 
most cited alterxlative agent by 63% in=%68)(Table 
3). TWO  (0.4%)  EFs repor-ted arI~yt'ranGas  in patitie~~ts 
who received droperidol, but no cleat115 were repomd. 
Opinion regarding overall utiiity of droperidol as a 
drug in the ED declined sig~ficantly  as a result of the 
FDA warning (P  < 0.009),  tvith ZOO (44%) EPs rat- 
ing droperidol as "extremely rascful'' prim to the U~~ITI- 
ing. and just 69 (15%) giving it the s;mx rating after 
the warning. Tlaree huladred and four respondents 
(67%) aaaswered that the FDA tc  arning had a direct 
affect on their ability to ireat patients in the ED Emer- 
gency physicians were q~~e~led  sn  their opm?on of the 
FDA warning, and 242 (53%) felt it was ur~justified. 
Twenty (4%) EQs  felt the warning was completely 
appropriate, and two (0.4%)  felt droperidol should 
be banned altogether. Onzly 37 (8%)  EBs reported 
they  were unconcerned with potential  loss of 
droperidol from the market, as has occurred in Eu- 
rope. 
DISCUSSION 
The results of this survey demonstrate the impact the 
FDA warning on dl-operidoi has had on prac"rcing 
EPs' use of the drug. Those paaicipating in the bur- 
vey now use droperidol rn~lch  less frequeaztly or not 
at all, and many now have no access to Qoper;dol. h 
also outlines the skepticism many EPs harbor towad 
the validity and ;113pmpnaateness of the FDA  wm~ing, 
md  that alternative naedicaiions may not be perceived 
to be as effective as dropesidol for a variety of indi- 
cations. The ackrraI practice experience of EPs does 
Table 2. Equal or More Effectwe Alterndt~z  e Drugs than 
Droper~dnl  for Aglratlon in i11e  ED 
11  -  @i?-) 
EP\ vl ho use or uced dropelidol 
for agitation  330  (100) 
Alternative  agents 
Haloperidol (HaldolO) 
Benzodiazepines 
Chlorpro~nazine  (Thorazine@) 
Barbiturates 
Propnfol (Diprn an@) 
R~speridoilc  iRisperdalO) 
01  anzapine (ZyprexaO) 
Thioridamne (Me!larilO) 
Fluphenazine (Prolixin@) 
Diphenhydramine (BenadrylO) Table 3. Equal or More Effective z41ternahve  Drugs than 
Droperidol for Nausea and EmeGs in the ED. 
n  -  IC/c) 
EPs t\ no use or used droperrdol 
for anuemes1s  8  (ICQ 
Promethazine (Phei~erganO) 
Meroclopramide (RcglanBj 
Onclansetroll (Zofran8) 
Prochiorperazi~~e  (CorngazineO) 
Hydrosyzine (VistarilO) 
Ibiphei~i~ydl-amim  (Bei~adrylO) 
Meclirine (Ailti\ ertO) 
Trimethobenzamide (TiganB) 
Dolasetiorl!A~~zernet@) 
Lorazepam (A:ivanO) 
Scopoiair~ine  (Transberm ScopO) 
Granisetron il<.ytril,B) 
I)examethasone  (DecadmnG) 
Ginger root 
not seer11 to reflect the poter~tial  -for  adverse outcoime 
as stated by the FDA,  Viihat  is unique about 
&opekdl;":i.  if is one of the  dmgs used fcj;  a wide 
r~l-~ge  i_-  of  sce~iinglgi  ~:nreiated  clinical indcal'roi.s, as 
.~.  %.  refiecred  311  recent emergency mecI.~cme  iitera- 
5.7  iC. i9-2i its ey  ,.. ,\ 
A -,  ~  ~rl~~t~j  md  exbeineky ihsw cost -spay 
also exp1i.n the outcTy  f:hat  accompa.~~':cd  'its loss in 
Europe"  Mter file co~nplete  avi tl~ds-k~~h~d  of tboperidol 
in  Europe by 95s rna~au&~-l,ctui~er  Janssen-Giiag,  Trzme~. 
arnd  cofieagues emphasized the d'iscsntinurdon was 
in response to adverse events liraited with chronic, 
1argc  k  or;?%  ~OS~S  given to psvchn:'  1  rii~i  "-'  IC p&t$iie~~tS,  1109 the 
sIq  I a1  qa3-  bl ;ntravealo~s  -.  doses give11  $0  POTPJ  patient^.^" 
r 7  !:his grou~  called for a distirsciion to be made be- 
+<   en  '=  the two indications so that low-dose i111rave- 
niius dropefidol could be used in the perjoperative 
setting. I-Hiaines et a1 also emphasized this distinction, 
and mentioned the consequences to the national he~alth 
budget in the Lhnited Kh~gdom  Gor-n  loss of &ope~idol 
and rise of the newer serotonin type 3  antagonist^.^' 
A similar protest was heard frorn Lehot and Ferry in 
France,.Q 
FoilovV~ing  the FDA wi~~icg,  an even stronger outc~=y 
occu~~ed  in the United States, In an article investigat- 
ing the actual adverse outcomes listed by the FDA, 
Horo\vitz and associates, refenjng to droperidol as 
"one of the most used emergency medications now," 
suggested the link between droperidol and QT inter- 
val prolongation. torsade de pointes, and sudden c;~- 
diac death was not at a13 clear.'  They noted many of 
the deaths or adverse outcolnes provided by the FDA 
were patients who were already critically ill and/or 
concomitantly  taking  several  potea~tially 
mhytlmoge~lic  ~~~edirsations.  Bailey et d  similzly in- 
vestigated the actual adverse cases used by the FDA 
to  justify the wdming  and reached the same conclm- 
sion."  Can and colleagues determined the cost of 
preventing PONV was over 40 times higher to the 
patient when ondansetron was used indead of 
droperidol. and "rat  prior to ihe FDA warnirrg 
droperidof had a 50% ~onarhet  share.:"  Thic group 
wrote "we believe thas the recent black box warning 
by the FDA  is totally unj~~stified,"  and called for the 
FDA to lift the ban $'or Iow-dose droperidol. 
Kintear  emphasized the seroto9ln type 3 antagonists, 
s~~h  as ondansetron and doiasetron, also bad poten- 
tial for QT mter\ al  plolongat~on  allhi torsade de pointes 
that .ji as Iargely bekg ignored by the FDA'?  An up- 
Gated Lrst of dri~gs  that prolong llle QT ~nterval  or 
1Pldtlce torsack de pomtes may by forind on the 111ternet 
($;a, x,irMcx~a~c~~).  and incidde chlorprsaraz~ne, 
~loEase~zon,  ~Joperidol,  nspendone. Ihiofida~ine,  and 
~:prassdone,  dl dn~~ig~  I1sted31 by surtey respofidents as 
potenanal altenxabtes to dr-operidok (Tables 2 and 3). 
Ma24 EPs and anestl-ies~olsgisr  are concerned that 
t~~a  ,lAb  iestrictior~  of droperidol and huted  avaiiab~Ety  oi 
pochHoqerazln3eze  forcmg them to use of more ea- 
pensi\a: serotonin typc 3  antagonasts  srach  as 
i~ndansetroi~."  Thew drugs do not have a record of 
extz~slve  use, 111rmaq  have ssmlar adverse effects, aid 
are extremely expensave. 
LIMITATIONS 
The most important limitation ofthis study is that it is 
a survey based or? srzbjective answers and opinions 
of a small sarnple of EPs, z~d  nnay not reflect act~eal 
practice. F-kar"r~ermore,  those who responded may 
have been motivated to do so because of a stronger 
than a-zTerage  positive or negative opinion regarding 
droperidoi. There were many non-responders, and 
several inaccurate, invalid, of- expired e-mail ad- 
dresses. The loss of these potential survey partici- pants may have affected the results of the study. In  10.  Hick JE. Mahoney BD. Eappe M. Prehospital sedation 
order to maintain respondents' privacy, follow up sur- 
veys were not e-mailed to ~mn-i-esponders,  or to those 
5ublnikthg hcornpiete sweys.  Respo~lsients  may have 
felt their participation in the srervey would result in 
their e-mail identity being prolnulgated, 
CONCLUSION 
Among those EPs replying to this survey, use of 
droperidol decreased dramatically as a result of the 
FDA warning. Over half the suwey resporsdenks feel 
the FDA w~l~g  is u~~jusdfied  and are copzcerned by 
the pote~~tial  loss or h11311er rest~jction  of drope~dol  in 
the United States. Many of the d~xegs  listed by EPs as 
alternatives to droperidol, such as hitloperidol,  cMor- 
promazine, rispesidone, and dsIase&on  also have risk 
of QT intenla9 prolongation. Beca~rse  of limited alter- 
native therapies, as well as tlaeir side effect profile 
and expense, many EPs ,and anestl~esiologists  ques- 
tion the FDRs action. 
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Resident/Student Corner 
Training in emergency medicine is full of fascinating 
encounters. Over the course of medical school and 
residency we will amash a h~age  body of inta~agible 
experience. Much of this we share with our imedi- 
ate peers, residents, and classmates, as a para of our 
own coping and cahloguing mecl~misms.  However, 
much of it is also an important part of our learning 
process. I cannot begin to relay how much Y have 
learned, not from books (I will never read as much as 
my residency director would like me to) bent from the 
experience of my fellow residents. Not only have 1 
leafned about the practice of medicine, but about the 
practice of life as a medical professional. 
This ES  21  new section for this journal,  As it starads 
there are no official boursdaries. Wc (the colh"ective 
reiidentisaudent population) can fill it as we see fit. 
There are many o~atlets  for statishcalgy s~gniii'icant  rm- 
domized, Minded, meta-prospective studie5 about 
vasiable dosing of phenytoin in post-ictd rats. Hsw- 
ever, these are very few place$ to share on a wider 
front, the more nebulous. but nor necessarily less irn- 
portant experiential aspects of our training.  (Pva,7c>w. 
that sorinds abit hew-agey.') HopefuUy tkis will spark 
some interesting disc~rssio~~  and we can lem  aad laugh 
a little in the process. 
Submissio~~s  of any kind (interesting stories, poems, 
prose, fkt,  fiction, and outside-the-box research pro- 
posals)  nnay  be  sent  'so  Jason  Quinn 
jquirm@hghed~com, 